What is Model Medicines?
Founded in 2019 and headquartered in La Jolla, United States, Model Medicines leverages artificial intelligence and machine learning to revolutionize the drug discovery process. The company's core mission is to significantly decrease the time and expense involved in bringing new pharmaceuticals to market. By applying advanced computational techniques, Model Medicines aims to identify and develop novel therapeutic candidates more efficiently than traditional methods, positioning itself at the forefront of pharmaceutical innovation.
How much funding has Model Medicines raised?
Model Medicines has raised a total of $4.1M across 1 funding round:
Angel/Seed
$4.1M
Angel/Seed (2021): $4.1M with participation from Nex Cubed, 8VC, ParticleX, and Irving Investors
Key Investors in Model Medicines
Nex Cubed
Nex Cubed is a venture accelerator and startup studio focused on supporting underrepresented founders, aiming to promote diversity and inclusion within the startup ecosystem through accelerators and resources.
8VC
8VC is a technology investment firm that backs visionary teams and industry-transforming companies, with a focus on smart enterprise platforms across various sectors including healthcare and Bio-IT.
ParticleX
ParticleX is dedicated to accelerating tech startups in sectors like Big Data, AI, and Blockchain, focusing on collaboration and investment to foster innovation and success in advanced technologies.
What's next for Model Medicines?
The recent major strategic investment signals a pivotal growth phase for Model Medicines. This capital infusion is expected to fuel the expansion of its AI/ML platforms, enhance its drug candidate pipeline, and potentially facilitate strategic partnerships within the pharmaceutical and biotechnology sectors. The company's focus on efficiency and cost reduction in drug development positions it to address critical unmet needs in healthcare, making it a noteworthy player in the competitive biotech landscape.
See full Model Medicines company page
